(RLFTF) – StreetInsider.com Reports
-
Relief Therapeutics (RLFTF) Reports Positive 12-Month Stability Data for Inhaled and Intravenous RLF-100
-
Acer Therapeutics (ACER), Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
-
NRx Pharmaceuticals (NRXP) and Relief Enter Tentative Settlement
-
Relief Therapeutics and Acer Therapeutics (ACER) Announce EC Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
-
Acer Therapeutics (ACER) and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
-
NRx Pharmaceuticals (NRXP) filed a lawsuit on against Relief Therapeutic
-
Acer Therapeutics (ACER) Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
-
Acer Therapeutics (ACER) and Relief Therapeutics Announce FDA Acceptance of NDA for ACER-001 to Treat Urea Cycle Disorders
-
Acer Therapeutics (ACER) and Relief Therapeutics Announce Submission of NDA to U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
-
Relief Therapeutics (RLFTF) RLF-100 (aviptadil) Receives FDA Orphan Drug Designation
-
NRx Pharmaceuticals (NRXP) Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI Trial in the Nation of Georgia
-
Acer Therapeutics (ACER) Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
-
NRx Pharmaceuticals (NRXP) Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (BRPA)
-
Relief Therapeutics and Acer Therapeutics (ACER) Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-00
Back to RLFTF Stock Lookup